Replimune (REPL) Operating Expenses (2017 - 2025)

Replimune has disclosed Operating Expenses across 9 years of filings, most recently posting $71.9 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $71.9 million, up 8.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $325.9 million (up 35.2% YoY), and the FY2025 annual result was $261.6 million, up 11.44% from the prior year.
• Operating Expenses came in at $71.9 million for Q4 2025 at Replimune, down from $84.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $90.4 million in Q2 2025 to a low of $22.2 million in Q1 2021.
• The 5-year median for Operating Expenses is $56.1 million (2023), against an average of $53.0 million.
• Across the five-year window, Operating Expenses surged 65.67% in 2023 and retreated 7.7% in 2024, its largest moves.
• Replimune's Operating Expenses stood at $29.7 million in 2021, then soared by 40.18% to $41.6 million in 2022, then surged by 35.82% to $56.5 million in 2023, then increased by 16.77% to $66.0 million in 2024, then grew by 8.86% to $71.9 million in 2025.
• The last three Operating Expenses figures came in at $71.9 million (Q4 2025), $84.3 million (Q3 2025), and $90.4 million (Q2 2025), per Business Quant data.